Evidence map›Paper›PMID 30093970›Full record

ArticleOncotarget2018

A k-mer based transcriptomics approach for antisense drug discovery targeting the Ewing's family of tumors.

Andrew J Annalora, Shawn O'Neil, Jeremy D Bushman, James E Summerton, Craig B Marcus, Patrick L Iversen

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. A survey of k-mer methods and applications in bioinformatics.Computational and structural biotechnology journal · 2024
    Review
  2. Article
  3. Transcriptome-based design of antisense inhibitors potentiates carbapenem efficacy in CREProceedings of the National Academy of Sciences of the United States of America · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Andrew J AnnaloraDepartment of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA.
Shawn O'NeilCenter for Genome Research and Biocomputing, Oregon State University, Corvallis, OR 97331, USA.
Jeremy D BushmanOnco-Tools, LLC, Philomath, OR 97370, USA.
James E SummertonOnco-Tools, LLC, Philomath, OR 97370, USA.
Craig B MarcusDepartment of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA.
Patrick L IversenDepartment of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA.
Oregon State University · USBiocom · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ewing's sarcoma treatment failures are associated with high mortality indicating a need for new therapeutic approaches. We used a k-mer counting approach to identify cancer-specific mRNA transcripts in 3 Ewing's Family Tumor (EFT) cell lines not found in the normal human transcriptome. Phosphorodiamidate morpholino oligomers targeting six EFT-specific transcripts were evaluated for cytotoxicity in TC-32 and CHLA-10 EFT lines and in HEK293 renal epithelial control cells. Average morpholino efficacy (EC

Indexed as

antisense oligonucleotidesEwing’s family of tumorsphosphorodiamidate morpholino oligomersRNA-based therapeuticstranscriptomics

Identifiers

PMID30093970
PMCPMC6078127
OpenAlexW2884649451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.